Unternehmens-Profil
Bayer AG is a global life science company operating in healthcare and nutrition sectors. It functions through three primary segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals segment develops prescription products for cardiology and women’s health, specialty therapeutics in oncology, hematology, ophthalmology, and cell and gene therapy, along with diagnostic imaging equipment and contrast agents. Consumer Health offers non-prescription items including dermatology treatments, nutritional supplements, digestive health aids, allergy relief, cough and cold remedies, and pain management solutions. Crop Science provides seeds, plant traits, crop protection products, digital farming solutions, and services to advance sustainable agriculture. Founded in 1863 and headquartered in Leverkusen, Germany, Bayer AG impacts pharmaceuticals, agriculture, and consumer wellness industries by innovating in drug development, such as stem cell therapies for Parkinson’s disease, and agricultural technologies. With a workforce of around 90,000 employees, it plays a significant role in addressing global health and food security challenges through its diversified portfolio.
Bewertungs-Kennzahlen
Allgemeine Finanzkennzahlen
Chart · 90 Tage
Letzter Kurs: 37,43 EUR· Stand 07.05.2026
News · Bayer AG
- Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis
- Bayer and bp Form Strategic Alliance to Jointly Scale Camelina as Intermediate Crop for Biofuels
- Bayer says its experimental blood thinner cuts risk and severity of repeat strokes
- Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion
- Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal